HVRRICANE study makes significant progress in paediatric HIV research

27 May, 2024

We are pleased to announce the successful completion of recruitment for the HVRRICANE study. The study, a collaboration between Penta, Bambino Gesù Paediatric Hospital in Rome (OPBG), the Henry M. Jackson Foundation for the Advancement of Military Medicine, and FAMCRU (a clinical research centre within Stellenbosch University in Cape Town, South Africa), has enrolled its target of 25 children and adolescents living with HIV in South Africa.

These participants represent a unique group: children and adolescents who acquired HIV around the time of birth and have been on antiretroviral therapy (ART) from the young age of 6 months to control the virus. The HVRRICANE study aims to understand how these individuals respond to specific vaccinations and treatments.

The primary focus is to measure the levels of HIV reservoirs in these young people before and after receiving the HIVIS DNA ± Cervarix and MVA-CMDR vaccine. Reservoirs are hidden pockets of the virus that remain in the body despite ART treatment. This information will be crucial in developing strategies to reduce the HIV reservoir and potentially achieve a cure.

Additionally, the study will assess the participants HIV-specific cellular response, which refers to the immune system’s ability to recognise and fight HIV. By understanding both aspects, researchers hope to pave the way for exciting advancements in paediatric HIV care.

The collaboration between the HVRRICANE partners and the dedicated participation of children and their families underlines a shared commitment: to advance scientific knowledge and ultimately work towards an HIV-free future. While preliminary results are expected by the end of the year, the potential impact of HVRRICANE is already generating significant anticipation.

This project has received funding from Penta and the National Institutes of Health (NIH) under Award No. U01AI135941. It is sponsored by Penta.

Learn more about HVRRICANE.